Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Deals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Fineline Cube Aug 18, 2026
Company Deals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Fineline Cube Aug 18, 2026
Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Fineline Cube Aug 18, 2026
Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Fineline Cube Aug 18, 2026
Company Deals

ICE Bioscience Secures Series B+ Financing to Boost Integration Capabilities

Fineline Cube Aug 3, 2023

Beijing-based Contract Research Organization (CRO) ICE Bioscience has reportedly raised close to RMB 100 million...

Company Drug

Sumitomo Pharma and Otsuka’s Ulotaront Fails to Meet Primary Endpoint in Schizophrenia Trials

Fineline Cube Aug 3, 2023

Japan-based Sumitomo Pharma Co., Ltd (TYO: 4506) and Otsuka Pharmaceutical Co., Ltd (FRA: OS1) have...

Company

Siemens Healthineers Reports 3.6% YOY Revenue Growth in Q3 2023 Financials

Fineline Cube Aug 3, 2023

Germany-based life sciences giant Siemens Healthineers AG (ETR: SHL) has released its financial results for...

Company Deals

Biogen Inc. to Acquire Reata Pharmaceuticals in $7.3 Billion Deal

Fineline Cube Aug 2, 2023

US-based Biogen Inc., (NASDAQ: BIIB) has announced that it has reached an agreement to fully...

Company

Pfizer Inc. Reports Q2 2023 Revenues, Signals Shift Beyond COVID-19 Products

Fineline Cube Aug 2, 2023

US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the second...

Company Deals

EQRx Inc. to be Acquired by Revolution Medicines in All-Stock Transaction

Fineline Cube Aug 2, 2023

US-based EQRx Inc. (NASDAQ: EQRX) has revealed that a definitive agreement has been signed for...

Company Deals

GSK Partners with Zuellig Pharma for Vaccine Distribution and Cold-Chain Management in Asia-Pacific

Fineline Cube Aug 2, 2023

GlaxoSmithKline (GSK; NYSE: GSK), a leading global vaccine manufacturer, has signed an agreement with Philippines-based...

Company Drug

Luye Pharma’s Parkinson’s Disease Treatment LY03003 Receives NMPA Review Acceptance

Fineline Cube Aug 2, 2023

Luye Pharma Group (HKG: 2186) has announced that the National Medical Products Administration (NMPA) has...

Company Deals

Mabwell Bioscience Secures Licensing Deals for Denosumab Biosimilars in Egypt and Pakistan

Fineline Cube Aug 2, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced separate licensing and commercialization agreements...

Company Deals

GeneMind Biosciences Secures RMB 400 Million in Series C Financing to Expand Gene Testing

Fineline Cube Aug 2, 2023

Shenzhen-based DNA sequencer specialist, GeneMind Biosciences Co., Ltd, has reportedly raised RMB 400 million in...

Company Deals

Guangzhou Wondfo Biotech Partners with Indonesia’s Kimia Farma in IVD Field

Fineline Cube Aug 2, 2023

China-based Guangzhou Wondfo Biotech Co., Ltd (SHE: 300482) has entered into a partnership with Indonesia’s...

Company Deals

InxMed Partners with GeneQuantum Healthcare to Develop Innovative ADCs

Fineline Cube Aug 2, 2023

China-based firm InxMed (Nanjing) Co., Ltd has announced a strategic partnership with compatriot firm GeneQuantum...

Company Deals

Sansure Biotech Partners with Indonesian Firm for Localized Molecular Diagnostic Production

Fineline Cube Aug 2, 2023

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has announced a strategic partnership with...

Company R&D

Sinopharm Partners with Harbin Institute of Technology to Boost Biomedical Industry Innovation

Fineline Cube Aug 2, 2023

China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strategic partnership with Harbin...

Company Deals

NK Celltech and RongCan Biotech Partner to Advance mRNA NK Cell Therapy and LNP Delivery System

Fineline Cube Aug 2, 2023

Shanghai-based NK Celltech and RongCan Biotech have entered into a partnership agreement to establish a...

Company Drug

Abbisko Therapeutics Initiates Phase II Clinical Trial for Pimicotinib in Tendon Sheath Giant Cell Tumor

Fineline Cube Aug 2, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the dosing of the first...

Company Deals

CASI Pharmaceuticals Enters Assignment Agreement with Mundipharma for Folotyn Commercialization in China

Fineline Cube Aug 2, 2023

US-based CASI Pharmaceuticals Inc., (NASDAQ: CASI) has announced the execution of an assignment agreement with...

Company Drug

Astellas Pharma’s Zolbetuximab BLA Accepted by China’s CDE for Gastric Cancer Treatment

Fineline Cube Aug 2, 2023

Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that the Center for Drug Evaluation (CDE)...

Company Deals

Shanghai Junshi Biosciences Partners with Zein Biotechnology for PCSK9 mAb Commercialization in China

Fineline Cube Aug 2, 2023

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced a partnership with...

Company

MSD’s Q2 2023 Earnings: Keytruda and Gardasil Drive Growth Amid COVID-19 Sales Decline

Fineline Cube Aug 2, 2023

US-based major Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) has released its financial results...

Posts pagination

1 … 537 538 539 … 709

Recent updates

  • OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties
  • European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets
  • Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform
  • Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors
  • CANbridge Pharmaceuticals’ Livmarli Granted NHIA Reimbursement Approval in Taiwan – IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.